Open AccessThe role of ß2-adrenergic receptor gene polymorphisms in the pharmacological response to bronchial asthma therapy
Author(s) -
К С Павлова,
D.S. Mdinaradze,
И.А. Кофиади,
О М Курбачева
Publication year - 2019
Publication title -
rossijskij allergologičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 2686-682X
pISSN - 1810-8830
DOI - 10.36691/rja16
Subject(s) - asthma , pharmacotherapy , medicine , adrenergic receptor , pathogenesis , allele , pharmacogenetics , receptor , adrenergic , polymorphism (computer science) , bioinformatics , gene , immunology , genotype , biology , genetics
This article represents an abstract and analytical review of studies devoted to the polymorphisms of β2-adrenergic receptor gene (ADRB2) and their associations with the degree of severity of bronchial asthma (BA) and response to standard pharmacotherapy. The results of the analysis showed a high heterogeneity of the data obtained, which is aggravated by different goals, objectives and study design. If the polymorphism of ADRB2 gene affects the expression of this receptor, it is possible that these asthma patients will show a low response to SABA / LABA; short- and long-acting anticholinergics will be preferred as bronchodilators. It is impossible to make a unique conclusion about the association between the polymorphisms of ADRB2 gene and the SABA / LABA responsiveness according to the results of analyzed publications. Data of the prevalence of homozygous alleles and studied associations among different populations are contradictory. Achievement of the asthma symptoms control is the main goal of asthma therapy. At the same time it’s impossible for a limited number of asthma patients in spite of the provision of current effective pharmacological resources. These aspects necessitate the research of the molecular-genetic mechanisms of pathogenesis in order to improve diagnostics and individual approach to the pharmacotherapy choice for patients with poor asthma control.